This year’s BIO International Convention in the US saw the strongest ever participation from South Korea, with 544 companies from the relatively small country reportedly registered and the number of Korean attendees the second-largest after the US, despite overlapping events such as the American Society of Clinical Oncology meeting and Jefferies NY Healthcare conference.
Feeling The 'K-Bio' Partnering Fervor In Boston: PharmAbcine’s Story
World-First IND Approval
With Korea accounting for the second-highest number of attendees after the US this year, the BIO International Convention was crowded with biopharma firms from the country looking for partnerships. PharmAbcine CEO Jin-San Yoo shared his experience of the event and provides updates on key R&D programs including a unique TIE2 agonist antibody.
